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Abstract
The three-dimensional X-ray crystal structure of carboxypeptidase A, a zinc-dependent hydrolase,
covalently modified by a mechanism-based thiirane inactivator, 2-benzyl-3,4-epithiobutanoic acid,
has been solved to 1.38 Å resolution. The interaction of the thiirane moiety of the inhibitor with
the active site zinc ion promotes its covalent modification of Glu-270 with the attendant opening
of the thiirane ring. The crystal structure determination at high resolution allowed for the clear
visualization of the covalent ester bond to the glutamate side chain. The newly generated thiol
from the inhibitor binds to the catalytic zinc ion in a monodentate manner, inducing a change in
the zinc ion geometry and coordination, while its benzyl group fits into the S1′ specificity pocket
of the enzyme. The inhibitor molecule is distorted at the position of the carbon atom that is
involved in the ester bond linkage on one side and the zinc coordination on the other. This
particular type of thiirane-based metalloprotease inhibitor is for the first time analyzed in complex
to the target protease at high resolution and may be used as a general model for zinc-dependent
proteases.
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Metalloproteases from the M14 family (carboxypeptidases, CPs) are involved in many
physiologic and pathological processes such as tissue organogenesis (1–3), acute pancreatitis
(4,5), diabetes (6,7), inflammation (8,9), fibrinolysis (10,11), neurologic diseases (12), and
cancer (13–16). Circulating forms of CP may be used as prognostic tools for the early
detection of cancer and other diseases (17). The M14 family of proteases comprises an
extended and complex array of zinc-dependent proteins with wide genomic distribution (18–
20). They share with matrix metalloproteases (MMPs; e.g., gelatinases, collagenases,
matrilysins, and stromelysins) a similar catalytic mechanism, whereby the catalytic zinc ion
predisposes the substrate to turnover with the involvement of a conserved glutamate residue
in the active site (21). Notwithstanding the shared features of their respective mechanisms,
MMPs are endopeptidases, whereas CPs are exopeptidases that remove the C-terminal
residues from peptide substrates.
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Most known small-molecule inhibitors of CPs are chelators of the active site zinc ion. These
chelators are often non-discriminant, as their function hinges on coordination with metals.
The limited selectivity among potent zinc chelators can be exemplified by thiol-dependent
CP inhibitors, such as 1 (2-mercaptomethyl-3-guanidino-ethylthiopropanoic acid,
Plummer’s inhibitor (22)), which was still found to inhibit other M14 proteases (23). A
similar concern has been encountered in the development of MMP inhibitors with subtype
selectivity (24). Mechanism-based inactivators (‘suicide substrate’ or ‘kcat inactivator’)
exploit features of the catalytic mechanisms of the targetted enzymes (25). An innocuous
agent is converted to the inhibitory species only within the active site of the target enzyme.
Compound 2, 2-((4-phenoxyphenylsulfonyl)methyl)thiirane, SB-3CT, is a prototypical
example. It was designed as a selective gelatinase (MMP-2 and MMP-9) inhibitor. Its
unique features include a biphenyl moiety that would fit the S1′ pocket of gelatinases and a
thiirane ring able to revert into a thiol group upon enzymic reaction (26,27). The oxirane
counterpart to 2 is three orders of magnitude less potent than the thiirane (28).
Chemotherapeutic compounds that may be used as drugs or imaging agents targeted to M14
proteases are highly sought (18,29), and the complexity among CPs calls for the
development of selective compounds. Based on the notion that a covalently bound
mechanism-based CP inactivator might be an ideal starting point for such an endeavor, a
screening of our collection of thiirane-based MMP ligands (~500 compounds) against
representative M14 proteases was performed. Unfortunately, these molecules did not prove
efficacious in inhibition of these carboxypeptidases. We hasten to add that thiirane-based
inhibitors of MMPs have not been amenable to study of their structures in complex with the
MMPs by X-ray analysis, hence structural information is currenly lacking (30). In an effort
to elucidate the minimal structural motifs for inhibition of carboxy-peptidases by thiirane-
based inhibitors, we turned to two examples from the literature. Compound 3 (2-benzyl-3,4-
epithiobutanoic acid), as well as its oxirane version, 4 (2-benzyl)-3,4-epoxybutanoic acid),
have been reported as mechanism-based inactivators of carboxypeptidase A (CPA) (31–33).
An earlier structural determination of CPA in complex with oxirane 4 (34,35) has been
reported, although the atomic coordinates have not been deposited. Kinetic results showed
that thiirane 3 and oxirane 4 displayed a similar inhibitory potency as CPA inactivators,
contrary to the example of gelatinase inhibition by 2.
We synthesized compound 3 for its study with CPA. Its binding to the active site would
allow for the coordination of the thiirane sulfur with the zinc ion, making the thiirane more
electrophilic and predisposing it to nucleophilic attack by the active site glutamate. Herein,
we report the X-ray structure of the enzyme inhibited by covalent modification with this
compound.
Methods and Materials
CPA crystals were grown from a 2 μL:2 μL mixture of enzyme solution (14 mg/mL in 0.02
M Tris, pH 7.5) and precipitant (20% PEG 3350, 0.2 M NH4Cl, 0.02 M Tris pH 7.0) by the
vapor diffusion method. The largest crystals were harvested and transferred to a 2 μL drop
containing the reservoir solution plus 10 mM of 3. Soaking lasted for one week before data
collection time, at which no crystal cracking or damage was evident. Crystals were
harvested, briefly bathed in cryoprotectant buffer (i.e., the reservoir solution with added
30% glycerol), flash frozen in nitrogen stream and diffracted. Some crystals gave excellent
quality diffraction images and that of the highest resolution was used for structure
determination by the molecular replacement procedure using native CPA (Protein Database:
2ctb) as the model. Programs from the CCP4 suite were used in different stages of structure
determination (36). Extra electron density was clearly evident in the region near the catalytic
zinc ion and was easily interpreted as the inhibitor molecule. Further, clear continuous
Fernández et al. Page 2













electron density unequivocally revealed the covalent linkage between the inhibitor and
Glu-270 side chain. The agreement between the model and the experimental observations is
excellent, as indicated by the crystallographic and refinement statistics (Table 1). Geometric
details of inhibitor–enzyme interactions are listed in Table 2.
Results and Discussion
The three-dimensional structure of the complex between CPA, a model zinc-dependent
protease, and a thiirane mechanism-based inactivator was solved to 1.38 Å resolution. The
CPA crystal structure presented herein is the highest resolution structure for this enzyme,
with a nearly 80% data completeness in the highest resolution shell. The structure has been
deposited with the PDB with accession code 3i1u. As shown in Figure 1, the existence of
continuous electron density between the bound inhibitor and the side chain of the glutamate
indicates that Glu-270, corresponding to the conserved active site glutamate of the zinc-
dependent proteases, is covalently modified by the inhibitor. The establishment of the
covalent bond is accompanied by the opening of the thiirane ring with the attendant
coordination of the newly formed thiol group with the catalytic zinc ion in a monodentate
manner. This arrangement gives a tetrahedral coordination sphere for the zinc ion, with three
ligands from the protein and the thiol from the inhibitor. Because thiiranes are quite stable at
physiologic pH, the involvement of the active site zinc ion is essential for the ring opening.
The coordinated thiol (likely as a thiolate) is the remnant of the interaction of the thiirane
sulfur, before the ring opening. Although inhibitor 3 was prepared as a racemic mixture, the
X-ray structure reveals that it is only the 2S,3S-3 configuration that fits into the electron
density map, indicating that the enzyme is enantioselective in its interaction with the
inhibitor. This configuration corresponds to that of the D-amino acid series, in accordance
with what has been observed for oxirane 4 (34,35).
When compared to the structure of the native CPA, some conformational changes occur
upon inhibitor binding. The catalytically important Tyr-248 (37) and Arg-145 have
experienced motion. Tyr-248 has been observed in two conformational states in the several
structures available for CPA. One brings it to a hydrogen bonding distance of the bound
peptide substrate (the ‘closed’ position) and the other is away from it (the ‘open’ position)
(38,39). In the X-ray structure of the inhibited complex, the Tyr-248 phenol group moves
from the surface closer to the active site cleft to make a strong hydrogen bond to the
carboxylate group of the inhibitor (the bond distance is 2.59 Å; the ‘closed’ position). This
carboxylate group, which corresponds to the terminal carboxylate of the peptide substrate, is
held in place by hydrogen bonds to the side chain of Arg-145 and Asn-144 Nδ1. The benzyl
ring of the inhibitor is buried in the S1′ pocket, thus interacting with Ile-255. This interaction
is believed to impart CPA selectivity toward hydrolytic processing of the C-terminal
hydrophobic amino acids. In this pocket, residues Leu-203 and Ile-243 make CH-π
interactions with the benzyl ring of the inhibitor. The presence of this benzyl ring displaces
the water molecules present in the native CPA S1′ pocket. A superimposition with the
related carboxypeptidae B (CPB) reveals that the benzyl moiety would clash with Asp-255
of CPB, which corresponds to Ile-255 of CPA, hence the origin of the likely selectivity for
CPA. The Glu-270 side chain conformation, which is covalently tethered to the inhibitor, is
approximately gauche (as measured by the Cα-Cβ-Cγ-Cδ dihedral angle of −74.4°). These
observations point to the fact that little changes in key microenvironments in the binding
pocket of the enzyme would allow for an exquisite recognition and binding of the ligand,
despite it being configurationally dissimilar to the natural peptide substrate.
The zinc environment is perturbed in the complex. The coordination number of the zinc ion
is four in the complex with the inhibitor and the resulting geometry is tetrahedral, with three
protein ligand atoms at the base and the thiol sulfur of the inhibitor at the apex of a regular
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tetrahedron. The Zn–N distances are equal (2.10 Å and 2.11 Å for His-69 and His-196,
respectively), while the Zn–S distance is 2.33 Å. The two Zn–O distances from the side
chain of Glu-72, the third coordinating amino acid, differ by almost 1 Å (2.04 versus 3.00
Å). This observation shows that Glu-72 is a monodentate ligand to the zinc ion. The
conformation of the glutamate carboxylate is syn as the O–C–O–Zn dihedral angle is
−2.56°. In the native CPA, the Zn coordination number is five because of the bidentate
coordination by Glu-72 (the Zn–O distances are 2.13 Å and 2.26 Å). A water molecule is at
the apex of the distorted tetrahedron, at a distance of 2.07 Å. Again, the conformation of the
glutamate carboxylate is syn (O–C–O–Zn = −1.69°). On the whole, the metal ion
environment is perturbed by the inhibitor in the CPA-bound structure.
The inhibitor adopted a trans conformation in binding to CPA (the main C1–C2–C3–S1
backbone dihedral angle is −162.4°). The C3–C4 and C3–S1 bond lengths are normal, 1.49
and 1.81 Å, respectively. The distance from C4 to Glu-270 Oε2, 1.61 Å, is longer than the
C–O ester bond distances reported in the other CPA structures (34,35). The C3–C4–Oε2
bond angle compares favorably to that seen in CPA inhibited by 2-benzyl-3-iodopropanoic
acid, a halogen-based covalent inhibitor of CPA: 114.3° versus 113.5° (40). The bond angles
to heavy atoms around C3 average 108.3°, with a minimum of 100.9° for C4–C3–S1. This
angle is below the ideal tetrahedral value of 109.5° indicating a distortion of the tetrahedral
geometry around C3 carbon. This carbon atom resides amidst the ester bond to Glu-270 side
chain and the zinc-coordinating sulfur, S1. Whether this distortion would have an effect over
the inhibitor binding to the enzyme, and hence to its inhibitory potency, might only be
assessed by analyzing compounds structurally related to the inhibitor analyzed here.
In summary, we observed in atomic detail the binding mode of a mechanism-based thiirane
inhibitor for CPA. The bound inhibitor fits in the S1–S1′ subsites of CPA, a model
metallopeptidase. The high-resolution complex between a zinc-dependent protease and a
thiirane-based inactivator has been obtained for the first time, allowing for a complete
analysis of the covalently modified protein. This structure constitutes the foundation for
future development of additional reagents targeting metallocarboxypeptidases.
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(A) The structure of the CPA-inhibitor complex. A2Fobs−Fcalc electron density map
showing the CPA active site with the product of the reaction of thiirane 3 with the enzyme.
The electron density map (chicken wire), calculated deleting the Glu-270 side chain and
inhibitor coordinates, is contoured at a 1.5σ level. The inhibitor and residues important for
binding are shown in capped sticks and are labeled. The catalytic zinc ion is in magenta,
while the sulfur atom from the inhibitor is in yellow. Other atoms are colored blue (nitrogen)
and red (oxygen). A continuous electron density is clearly seen along the bond linking
Glu-270 side chain and the inhibitor. (B) Schematic representation of the CPA-inhibitor
complex.
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Table 1
Statistics of data collection and refinement for inhibitor-bound CPA
Parameters Value
Wavelength used during data collection 0.8123 Å
Unit cell constants a = 42.32 Å, b = 57.50 Å, c = 57.08 Å
α = 90.0°, β = 99.1°, γ = 90.0°
Resolution range 31.27–1.38 Å
Space group P21 (1 mol/asymmetric unit)
Number of measured reflections 488 546
Number of unique reflections 54 345
Rmergea (overall/outermost shell) 6.8/37.9%
Completeness & multiplicity (overall/outermost shell) 96.6/77.8%
6.1/5.3
I/σI (overall/outermost shell) 8.8/1.8
Reflections used for refinement (total/test set) 52 590/1102
Crystallographic Rfactorb/Rfreec 14.3/15.7%
Deviation from ideality
 r.m.s.d. bond lengths 0.008 Å
 r.m.s.d. bond angles 1.14°
Number of protein atoms/total atoms 2438/2930
B-factor statistics (Å2)
 Overall B-factor/Wilson plot B-factor 10.7/9.3
 Catalytic domain, main/side chain 7.3/8.4
 Zn2+ (1 in total/1 mol per monomer) 5.3
 Inhibitor atoms (14 in total/1 mol per monomer) 5.8
 Glycerol atoms (42 in total/7 mols per monomer) 19.4
 Solvent atoms (435 in total) 26.0
Protein geometryd
 Ramachandran favored 97.3% (293 of 301 residues)
 Ramachandran allowed 99.7% (300 of 301 residues)
 Ramachandran outliers 0.3% (1 of 301 residues, Ser-199)
 Residues with bad bonds/angles 0.00/0.00%
 Rotamer outliers 0.77%
a
Rmerge = Σhkl Σj = 1 to N |Ihkl−Ihkl (j) |/Σhkl Σj = 1 to N Ihkl (j), where N is the redundancy of the data. The outer-most shell is 1.46–1.38 Å.
b
Rfactor = Σhkl ||Fobs|−|Fcalc||/Σhkl |Fobs where Fobs and Fcalc are the observed and calculated structure factor amplitudes of reflection hkl.
c
Rfree = Rfactor for a randomly selected 2% subset of reflections that were not used in refinement.
d
According to Molprobity (41).
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Table 2
Geometric details inhibitor–CPA interactions
Interaction Parameter (Å, °) Comments
Zn/His-69, Zn/His-196, Zn/Glu-72-Zn, Zn/S1 2.10, 2.11, 2.04, 2.33 Zinc coordination sphere
Glu-270 Oε2-C4 1.61 Covalent bond to nucleophile Glu-270
Tyr-248 OH-COOH 2.59 Hydrogen bond phenolic ring
Arg-145 Nη1-COOH 2.89 Salt bridge
Arg-145 Nη2-COOH 2.78
Arg-127 Nη2-COOH 3.35 Hydrogen bond of inhibitor COOH
Asn-144 Nδ1-COOH 2.97
Leu-203 Cδ1-Cphenyl 3.85 Hydrophobic interactions of the benzyl ring (selected)
Ile-243 Cδ1-Cphenyl 3.42
Thr-268 Cγ2-Cphenyl 3.68
C3–S1, C4–C3–S1 1.81, 100.9 Geometry around the sulfur
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